SUSTAINED REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS- EVIDENCE FROM A COHORT FOLLOWED-UP AT A CENTER OF EXCELLENCE IN COLOMBIA

Author(s)

Alvis-Estrada J1, Santos-Moreno P2, Alvis-Zakzuk NJ3, Villarreal Peralta L2, Buitrago-Garcia D4, Carrasquilla-Sotomayor M5, Alvis-Zakzuk NR5, Alvis-Guzman N6
1ALZAK Foundation, Cartagena, Colombia, 2Biomab, bogota, Colombia, 3Universidad de la Costa-CUC, Barranquilla, Colombia, 4SIIES- Investigación y educación en salud, BOGOTA, Colombia, 5ALZAK Group, Cartagena, Colombia, 6ALZAK Group, Cartagena, BOL, Colombia

OBJECTIVES To describe how it is possible to maintain in remission a cohort of patients in conventional treatment for rheumatoid arthritis (RA), avoiding quickly passing to biological therapy.

METHODS We conducted a descriptive study in patients with RA treated at a Center of Excellence (CoE) for RA in Bogotá-Colombia. Patients were followed-up during 2018 using a treat-to-target strategy with a patient-centered care model. At the CoE, a patient should be evaluated by rheumatologist, physical and occupational therapist, physiatrist, nutritionist and psychologist, at least three times per year. The CoE strategy ensures the adherence of RA patients, guaranteeing opportunity and accessibility to rheumatologists and allied healthcare services. Data were gathered from clinical records; descriptive statistics were estimated and association between clinical and demographic variables was studied by using the Chi-square test. A t-test for paired samples was used to describe the change in DAS28.

RESULTS We analyzed 1265 patients, 82.13% were women. The majority (97.15%) of patients were >40 years-old with average age of 63 years-old (SD: +/-12 years). Most (91.62%) of patients attended six medical appointments during a year, in contrast to the average of three visits per year reported by Colombian Cuenta de Alto Costo; that is why the patients who were in remission remained in the same status, preventing many of them from passing to costly biological therapy. DAS28 slightly decreased from the first appointment (DAS28=2.56) to the sixth one (DAS28=2.45) (p-value=0.0005). Regarding to the prevalence of comorbidities, varied by age groups of 41-50, 51-60, 61-70 and >70 years-old, with 14.29%, 21.84%, 37.73% and 58.24%, respectively [statistically different (p- value <0.0000)].

CONCLUSIONS Patients evidenced a high adherence to the appointments at the CoE. This model is successful, because it allows to keep patients in remission level of disease activity avoiding costly biologicals and impacting positively the budget for the health system.

Conference/Value in Health Info

2019-09, ISPOR Latin America 2019, Bogota, Colombia

Value in Health Regional, Volume 20S (October 2019)

Code

PMS1

Topic

Clinical Outcomes, Epidemiology & Public Health, Health Service Delivery & Process of Care

Topic Subcategory

Clinical Outcomes Assessment, Disease Management, Performance-based Outcomes, Public Health

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×